Survodutide – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity treatment.
This complimentary MARA Rating® report assesses Survodutide’s market-access risk profile for the treatment of obesity. The therapy received a MARA Score of 2.23 out of 4, corresponding to a Very Weak (B+) rating. In comparison, the therapeutic area 5-year average is 2.8 and the overall industry 5-year average is 3.0, placing Survodutide below both benchmarks.
Clinical Effectiveness: A+ (Very Strong)
In a Phase 2 trial, Survodutide achieved an average weight reduction of around 15% at 46 weeks versus standard of care (lifestyle intervention alone). This performance is comparable to semaglutide, reflecting a clear clinical advantage.
However, limitations include the lack of long-term outcome data and the absence of active comparator trials, which weakens the overall strength of evidence.
Comparator Selection: B++ (Marginal)
The trial design utilized placebo plus lifestyle modification, appropriate for establishing efficacy, but without head-to-head active comparators. As a result, it is difficult to assess Survodutide’s relative performance against existing therapies.
Care-Pathway Integration: A+ (Very Strong)
Survodutide can be introduced into existing obesity management frameworks without requiring new diagnostics or significant adjustments. Its role as an adjunct to lifestyle modification is consistent with prevailing treatment guidelines, supporting ease of adoption.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk – clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more – each scored on a seven-level scale (A++ to C).
We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains – Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty – available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email sales@mararating.com to learn more and unlock your access.
Access this report and hundreds of others: https://mararating.com/mara-ratings-list
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer at mararating.com.